.Pharmacolibrary.Drugs.ATC.J.J01MA12

Information

Levofloxacin is a broad-spectrum third-generation fluoroquinolone antibiotic, primarily used for the treatment of bacterial infections such as respiratory tract infections, urinary tract infections, and skin infections. It is approved and widely used in clinical practice today.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after single oral and intravenous doses.

References

1. Canouï, E, et al., & Benaboud, S (2022). Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections. The Journal of antimicrobial chemotherapy 77(5) 1344–1352. DOI:10.1093/jac/dkac031 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35178577

2. Boonpeng, A, et al., & Samaeng, M (2021). Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. Biopharmaceutics & drug disposition 42(7) 329–337. DOI:10.1002/bdd.2294 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34117648

3. Jaruratanasirikul, S, et al., & Samaeng, M (2018). Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 99(8) 886–892. PUBMED:https://pubmed.ncbi.nlm.nih.gov/29947489

Revisions

• 06/2025 initial generated model